Servier Pharmaceuticals LLC

BOSTON, Nov. 19, 2024 /PRNewswire/ -- Servier, a leader in delivering transformative new therapies to patients, and Dana-Farber Cancer Institute, a world leader in adult and pediatric cancer treatment and research, are proud to announce the enrollment of the first PhD student from Dana-Farber in the SHINEDocs program funded by Servier. This agreement marks the initiation of the SHINEDoc program in the U.S. where the PhD student will start in the program this November. The SHINEDoc program, standing for " Servier Highlighting Innovation through its NEtwork of PhD students and Post- Docs," is a dynamic, international community of more than 70 PhD and postdoctoral students working in either Servier laboratories or with Servier's partners. Those in the SHINEDoc program receive specific trainings to build their research acumen and soft skills, career support and networking opportunities within and outside of Servier. "Dana-Farber's clinical and scientific expertise are recognized worldwide, and we are excited to continue to build upon our relationship with the organization," said Walid Kamoun, Vice President, Global Head of R&D Oncology at Servier. "This collaboration is based not only on the shared vision of developing transformative therapies for cancer patients through scientific innovation, but to support up-and-coming researchers in the Boston area as well. Following the initiation of this partnership, we hope to include other U.S. organizations and universities in the SHINEDoc program." The first phase of this program will focus on the training of one PhD student in basic research in the field of oncology and neurological diseases. Over the course of the three-year program, the PhD student will join the international community of fellow doctoral students and postdocs to share knowledge, develop soft skills and build their international network. The aim of this program is to ultimately develop new technologies and characterize new therapeutic targets for the benefit of patients across the globe. "I am deeply grateful to Servier Pharmaceuticals for providing this opportunity to our graduate student," said Kevin Haigis, PhD., Chief Scientific Officer, Dana-Farber Cancer Institute. "This program not only provides critical financial assistance, but a strong commitment to mentor and support young scientists in their early career growth. The offerings provided via the SHINEDocs program cater to all facets of development from networking to training, career support and workshops. I am excited to partner with Servier Pharmaceuticals to share in the advancement of future talent at Dana-Farber." About Servier Pharmaceuticals Servier is a global leader in oncology, governed by a non-profit foundation. Servier approaches innovation with a long-term vision, free of influence from fiduciary responsibilities. Servier is the leader in IDH-mutant targeted therapies and devotes more than 65% of its research and development budget to Oncology. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its progression. Servier believes we can serve more people by helping the right patients find the right treatment, at the right time. Servier takes a One Innovation Engine approach to R&D and is actively seeking alliances, partnerships and acquisitions at various stages of the portfolio. For more information about working with Servier to bring the promise of tomorrow to the patients it serves, visit Servier.us. Media Contact : [email protected] SOURCE Servier Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Servier's presence at the 2024 ASH congress includes seven company-sponsored abstracts including one oral presentation Data supports Servier's unwavering commitment to patients living with IDH-mutated blood cancers BOSTON, Nov. 13, 2024 /PRNewswire/ -- Servier today announced that it will present data at the Annual Meeting for the American Society of Hematology (ASH), December 7-10, 2024 in San Diego, California. Data presentations will focus on the company's clinical and preclinical studies in IDH-mutated acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), providing new insights on existing programs and a better understanding of the challenges faced by people living with hematological malignancies. "Servier is driven to deliver innovative therapies for diseases where patient needs are not yet sufficiently met and where we believe we can have the greatest positive impact," said Becky Martin, PhD, Chief of Medical at Servier Pharmaceuticals. "We look forward to sharing data at this year's ASH annual meeting that build upon our expertise in developing medicines for patients living with hematological malignancies, including IDH-mutated AML and MDS." A full list of company-sponsored abstracts can be found here. About Servier in Oncology Servier is a global leader in oncology, governed by a non-profit foundation. Servier approaches innovation with a long-term vision, free of influence from fiduciary responsibilities. Servier is the leader in IDH-mutant targeted therapies and devotes more than 65% of its research and development budget to Oncology. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its progression. Servier believes we can serve more people by helping the right patients find the right treatment, at the right time. Servier takes a One Innovation Engine approach to R&D and is actively seeking alliances, partnerships and acquisitions at various stages of the portfolio. For more information about working with Servier to bring the promise of tomorrow to the patients it serves, visit Servier.us. Media Contact Sara Noonan [email protected] SOURCE Servier Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Servier's presence at the 2024 SNO congress includes six company-sponsored abstracts including three oral presentations BOSTON, Nov. 12, 2024 /PRNewswire/ -- Servier today announced that it will present data at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO), November 21-24, 2024, in Houston, Texas. Data presentations will focus on the company's neuro-oncology development program, including three oral-presentations, and reinforce our understanding of the burdens and experiences of people living with IDH-mutant glioma. "At Servier, we are dedicated to delivering transformative, life-changing therapies to patients living with cancer who have little-to-no options available," said Claude Bertrand, Executive Vice President Research and Development, Chief Scientific Officer, at Servier. "Our presentations at this year's Society for Neuro-Oncology Conference reinforce our commitment to people living with IDH-mutant gliomas, who had, until recently, limited therapeutic options to treat this devastating disease. We look forward to sharing results with the community, including updated Phase 3 data that supports our recently approved medication for Grade 2 IDH-mutant gliomas." A full list of company-sponsored abstracts can be found here. About Glioma1 Gliomas are tumors that arise from glial or precursor cells within the central nervous system (CNS). The 2021 World Health Organization (WHO) classification recognizes four general groups of gliomas, one of which is adult-type diffuse gliomas. These diffuse gliomas are the most common primary malignant brain tumors in adults. The pathogenesis and prognosis of these tumors are tightly linked to mutations (or lack thereof) in the metabolic enzyme isocitrate dehydrogenase (IDH), and molecular testing is required for proper diagnosis. As of 2021, adult-type diffuse gliomas are sub-divided into only three categories: Astrocytoma, IDH-mutant (CNS WHO grades 2-4) Oligodendroglioma, IDH-mutant and 1p19q-codeleted (CNS WHO grades 2-3) Glioblastoma, IDH-wildtype (CNS WHO grade 4) About Servier in Oncology Servier is a global leader in oncology, governed by a non-profit foundation. Servier approaches innovation with a long-term vision, free of influence from fiduciary responsibilities. Servier is the leader in IDH-mutant targeted therapies and devotes more than 65% of its research and development budget to Oncology. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its progression. Servier believes we can serve more people by helping the right patients find the right treatment, at the right time. Servier takes a One Innovation Engine approach to R&D and is actively seeking alliances, partnerships and acquisitions at various stages of the portfolio. For more information about working with Servier to bring the promise of tomorrow to the patients it serves, visit Servier.us. Media Contact Sara Noonan [email protected] Ken DiCienzo [email protected] References 1 Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy, T. F. (2023). Vorasidenib in idh1- or IDH2-mutant low-grade glioma. New England Journal of Medicine, 389(7), 589–601. SOURCE Servier Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED